Abstract
Exelixis claims a series of RAF kinase inhibitors based on a 3-oxo-2,3-dihydro-1H-isoindol-1-yl core structure. Both the chemical matter and the biochemical target appear to be new for Exelixis, and many examples have IC50 values < 100 nM. These compounds are claimed to have the potential to treat diseases that are associated with uncontrolled, abnormal and/or unwanted cellular activities such as cancer.
Keywords::
Disclaimer
The author is writing in his individual capacity and not as a representative of his employer.
Patent Details
Title RAF modulators and methods of use
Assignee Exelixis, Inc.
Inventors Anand NK, Blazey CM, Bowles OJ et al.
Priority date 07/05/2004
Filing date 25/03/2005
Publication date 01/12/2005
Publication no. WO2005112932